Matsui et al.[1515 Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd,
et al. 2010 Rheumatoid arthritis classification criteria: an American College of
Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis
Rheum. 2010;62:2569–81.
]
|
Experimental study |
5 |
4 |
PET |
- |
Macroautoradiography, Histology |
To Compare PET with macroautoradiography and histology |
Okabe et al.[1616 Okabe T, Shibata H, Shizukuishi K, Yoneyama T, Inoue T, Tateishi U. F-18
FDG uptake patterns and disease activity of collagen vascular diseases-associated
arthritis. Clin Nucl Med. 2011;36:350–4.
]
|
Retrospective clinical study |
72 patients (30 with RA) |
- |
PET ou PET/CT |
19 |
- |
Diagnosis |
Elzinga et al.[1919 Elzinga EH, van der Laken CJ, Comans EF, Lammertsma AA, Dijkmans BA,
Voskuyl AE. 2-Deoxy-2-[F-18]fluoro-D-glucose joint uptake on positron emission
tomography images: rheumatoid arthritis versus osteoarthritis. Mol Imaging Biol.
2007;9:357–60.
]
|
Crossover clinical study |
14 with RA, 6 with OA |
5 with FM |
PET |
22 |
- |
Diagnosis |
Palmer et al.[2121 Palmer WE, Rosenthal DI, Schoenberg OI, Fischman AJ, Simon LS, Rubin RH,
et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR
imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology.
1995;196:647–55.
]
|
Crossover clinical study |
12 with UA |
- |
PET |
1 |
MRI |
Assessment of disease activity |
Roivanen et al.[2020 Roivainen A, Parkkola R, Yli-Kerttula T, Lehikoinen P, Viljanen T,
Möttönen T, et al. Use of positron emission tomography with methyl-11C-choline and
2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the
assessment of inflammatory proliferation of synovium. Arthritis Rheum.
2003;48:3077–84.
]
|
Prospective clinical study |
2 with RA, 6 with UA, 1 with AS, 1 USA |
- |
PET |
1 |
Contrast- enhanced MRI |
Assessment of disease activity |
Beckers et al.[2222 Beckers C, Ribbens C, André B, Marcelis S, Kaye O, Mathy L, et al.
Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Nucl
Med. 2004;45:956–64.
]
|
Prospective clinical study |
21 with RA |
13 without arthralgia |
PET |
12 or 22 |
US, SDAI, DAS28
|
Assessment of disease activity |
Goerres et al.[2323 Goerres GW, Forster A, Uebelhart D, Seifert B, Treyer V, Michel B, et
al. F-18 FDG whole-body PET for the assessment of disease activity in patients with
rheumatoid arthritis. Clin Nucl Med. 2006;31:386–90.
]
|
Prospective clinical study |
7 with RA |
- |
PET |
28 |
DAS28, RDAI |
Assessment of disease activity |
Kubota et al.[2424 Kubota K, Ito K, Morooka M, Mitsumoto T, Kurihara K, Yamashita H, et al.
Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med.
2009;23:783–91.
]
|
Retrospective clinical study |
18 with RA |
- |
PET/CT |
13 |
CRP, joint count |
Assessment of disease activity |
Beckers et al.[2525 Beckers C, Jeukens X, Ribbens C, André B, Marcelis S, Leclercq P, et al.
(18)F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic
resonance and sonographic assessments as well as with the serum level of
metalloproteinase-3. Eur J Nucl Med Mol Imaging. 2006;33:275–80.
]
|
Cohort study |
16 with RA |
- |
PET |
1 |
US, MRI, CRP, MMP-3 |
Assessment of treatment response |
Okamura et al.[2626 Okamura K, Yonemoto Y, Arisaka Y, Takeuchi K, Kobayashi T, Oriuchi N, et
al. The assessment of biologic treatment in patients with rheumatoid arthritis using
FDG-PET/CT. Rheumatology (Oxford). 2012;51:1484–91.
]
|
Cohort study |
22 with RA |
- |
PET/CT |
12 |
US, MRI, DAS28, DAS28-CRP, ESR, CRP, MMP-3,
RF |
Assessment of treatment response |
Elzinga et al.[2727 Elzinga EH, van der Laken CJ, Comans EF, Boellaard R, Hoekstra OS,
Dijkmans BA, et al. 18F-FDG PET as a tool to predict the clinical outcome of
infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med.
2011;52:77–80.
]
|
Exploratory study |
16 with RA |
- |
PET |
12 |
CRP, ESR, MHAQ, VAS |
Assessment of treatment response |
Sato et al.[29]
|
Prospective clinical study |
6 with RA |
- |
PET |
2 |
DAS28, joint count, ESR, CRP |
Assessment of treatment response |